United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $530.42, for a total transaction of $5,038,990.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $172,091,056.06. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Trading Down 0.8%

NASDAQ:UTHR opened at $523.63 on Wednesday. The company has a market cap of $22.23 billion, a P/E ratio of 19.33, a P/E/G ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The company’s 50-day moving average price is $546.23 and its 200-day moving average price is $532.01.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted $6.63 EPS. On average, analysts expect that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several recent research reports. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Finally, Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $648.33.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Torren Management LLC purchased a new position in United Therapeutics in the fourth quarter worth approximately $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at $31,000. International Assets Investment Management LLC lifted its stake in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB grew its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.